We have highlighted that plasma AD biomarker levels, directly related to AD neuropathologic burden, are associated with biological age acceleration in Hispanics, and that DNA methylation changes may be a relevant pathway for AD pathogenesis in APOE‐ε4 non‐carriers. The gene discussed is APOE; the disease is Alzheimer disease.